microdose glp-1 Microdosing GLP-1s: Does It Work? Risks and Benefits Is It Smart For You

GLP-1 drugs produce appetite suppression within days

Weggovy is recommended for those whose BMI is 30 or above or those, whose BMI is 27 and above and who have conditions such as type 2 diabetes or high blood pressure

Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs

3 To understand the relationship between GLP-1 medications and kidney function, as measured by creatinine lab results, we studied 108,439 adult patients who started semaglutide, liraglutide, or tirzepatide between 2021 and 2024 and had one or more creatinine labs in the months leading up to and following the new medication